Artificial Intelligence

The Regulatory Backdrop

Where "explain my labs" meets medical device

FDA guidance on clinical decision support (CDS) software clarifies which decision-support functions are regulated as medical devices and which are excluded. The guidance draws crucial lines: some software functions remain regulated depending on intended use and context. This regulatory framework shapes every AI health service—determining what claims can be made and what oversight applies.

The Regulatory Distinctions

The FDA distinguishes between software that provides information for clinicians to independently evaluate versus software that directly recommends specific actions. Products positioned as "helping you understand your data" face different requirements than products making diagnostic claims.

For luxury health AI services, this creates strategic choices. Staying in the wellness space—providing information without medical claims—allows faster deployment without regulatory burden. Crossing into medical device territory requires FDA clearance but enables stronger claims. The positioning shapes both marketing language and product design.

Why It Matters for Luxury

Regulation shapes what AI health services can promise and how they must operate. The luxury health AI landscape exists partly in the spaces regulation hasn't fully addressed—novel applications where rules are unclear, services positioned as wellness to avoid medical oversight. Understanding this regulatory backdrop reveals why certain claims appear in marketing and why certain questions go unanswered.

Primary Sources